Oncology, Respiratory, TMM
Read Time: 2 mins

World Lung Cancer Day 2022: Awareness to breathe easier

Copy Link
Published Online: Jul 25th 2022

Lung cancer is the most fatal cancer, responsible for the deaths of around 1.8 million people each year – and this number is climbing.

It’s also the most common lethal neoplasm in the world. Professor Gerard A. Silvestri (Medical University of South Carolina, SC, USA) highlights that, “lung cancer is the leading cause of death due to cancer worldwide.” An estimated 1.8 million new cases were diagnosed in 2012, making it “more common than breast cancer, colon cancer and prostate cancer combined… [killing] more women than all other female cancers combined.”

WATCH: Gerard A. Silvestri on Managing Complications in the Treatment of Lung Cancer (Part 1 | Part 2)

Its prevalence is attributable to many risk factors, including passive exposure to diesel exhaust fumes, workplace carcinogens, radon, asbestos and biomass fuels; but the overwhelming risk factor is smoking tobacco, which accounts for over 70% of cases.

Survival rates vary, with roughly 1 in 3 living for at least one year post-diagnosis and 1 in 20 making it past ten years. These rates differ broadly, with the early stage diagnosis vital to chances of survival. If left untreated and cancer spreads to other organs, 5-year survival is only around 13% – and advanced-stage lung cancer is incurable.

WATCH: Niels Reinmuth on the Characteristics of Long-term Survivors in the CASPIAN Study

These stark facts aside, with greater awareness and knowledge, there are steps we can take to fight back and tip the scales.

That’s why we celebrate World Lung Cancer Day on 1 August 2022.

Started by the Forum of International Respiratory Societies (FIRS) in 2012, this important day is dedicated to raising issues and reminding us that in its early stages, lung cancer is treatable (and curable) with curative-intent surgery and radiation therapy. Also, preventative steps can minimise the chances of developing lung cancer – on both personal and global levels.

WATCH: Misako Nagasaka on the Results of the TRUST-II Study

Awareness on multiple fronts is vital, advocating for:

  • advice on risk factors and how to minimize their impact (personally and globally)
  • education on early screening and recognizing symptoms
  • encouraging a global effort to address inequalities in care and access to treatments
  • increasing funding towards better screening methods and improved therapies 

touchONCOLOGY and touchRESPIRATORY support World Lung Cancer Day and aim to spread greater awareness about this common and fatal cancer. Learn about lung cancer by visiting our oncology and respiratory libraries of video interviews, conference highlights, journal articles and clinical trial updates.

Alternatively, you can get in touch to learn how you can benefit from our educational activities and regularly updated content.

Share this Article
Related Content In TMM
Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72